keyword
MENU ▼
Read by QxMD icon Read
search

Mullerian cancer

keyword
https://www.readbyqxmd.com/read/29330698/circulating-hormones-and-mammographic-density-in-premenopausal-women
#1
Kimberly A Bertrand, A Heather Eliassen, Susan E Hankinson, Bernard A Rosner, Rulla M Tamimi
Prior research suggests that several endogenous hormones in premenopausal women are associated with breast cancer risk; however, few studies have evaluated associations of endogenous hormones with mammographic density (MD) in premenopausal women. We conducted a cross-sectional study of plasma hormone levels in relation to MD among 634 cancer-free premenopausal women in the Nurses' Health Study II. We measured percent MD from screening mammograms using a computer-assisted method. We assayed estradiol, estrone, and estrone sulfate in blood samples timed in early follicular and mid-luteal phases of the menstrual cycle as well as testosterone, androstenedione, progesterone, dehydroepiandrosterone (DHEA), DHEA sulfate, sex hormone-binding globulin (SHBG), and anti-Müllerian hormone in luteal or untimed samples...
January 12, 2018: Hormones & Cancer
https://www.readbyqxmd.com/read/29315564/circulating-anti-m%C3%A3-llerian-hormone-and-breast-cancer-risk-a-study-in-ten-prospective-cohorts
#2
Wenzhen Ge, Tess V Clendenen, Yelena Afanasyeva, Karen L Koenig, Claudia Agnoli, Louise A Brinton, Joanne F Dorgan, A Heather Eliassen, Roni T Falk, Göran Hallmans, Susan E Hankinson, Judith Hoffman-Bolton, Timothy J Key, Vittorio Krogh, Hazel B Nichols, Dale P Sandler, Minouk J Schoemaker, Patrick M Sluss, Malin Sund, Anthony J Swerdlow, Kala Visvanathan, Mengling Liu, Anne Zeleniuch-Jacquotte
A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a consortium study including ten prospective cohorts that had collected blood from premenopausal women. A nested case-control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ (20%) breast cancer cases were individually matched to controls (n = 3,122) on age at blood donation...
January 8, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29302874/anti-m%C3%A3-llerian-hormone-in-pre-menopausal-females-after-ablative-radioiodine-treatment-for-differentiated-thyroid-cancer
#3
Massimo Giusti, Miranda Mittica, Paola Comite, Claudia Campana, Stefano Gay, Michele Mussap
PURPOSE: In recent years, anti-Mullerian hormone (AMH) has been considered a reliable index of ovarian reserve. There are few data on AMH values in thyroid cancer. The aim of this study was to evaluate AMH levels in pre-menopausal women with a history of low-risk thyroid cancer. METHODS: Thirty-four women (aged 40.7 ± 6.7 years) were studied 7.1 ± 0.9 years after surgery and at least one RAI treatment. A group of 23 thyroid cancer women (41.6 ± 7...
January 4, 2018: Endocrine
https://www.readbyqxmd.com/read/29288227/endobronchial-metastasis-of-mixed-mullerian-tumour-of-the-uterus
#4
Vadsala Baskaran, Laura Pugh, Robert James Berg, John Anderson
Endobronchial metastasis occurs in only 2%-5% of non-pulmonary cancers. Here we report on an 84-year-old woman who presented with breathlessness and light-headedness while on holiday in Australia, 2 years post-treatment for endometrial cancer. Initial CT pulmonary angiogram identified a soft tissue mass in the left hemithorax. A chest radiograph performed after repatriation was consistent with a large left pleural effusion, but bedside ultrasound showed a lobulated mass involving the left hemidiaphragm. A pleural procedure in the traditional 'triangle of safety' would have resulted in inadvertent puncture of the underlying mass...
December 28, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29246176/evaluation-of-three-dimensional-sonoavc-ultrasound-for-antral-follicle-count-in-infertile-women-its-agreement-with-conventional-two-dimensional-ultrasound-and-serum-levels-of-anti-m%C3%A3-llerian-hormone
#5
P A Peres Fagundes, R Chapon, P R Olsen, A K Schuster, M M C Mattia, J S Cunha-Filho
BACKGROUND: Several studies have reported a correlation between antral follicle count by conventional 2D transvaginal sonography and serum anti-Müllerian hormone levels. However, few studies have investigated the effectiveness of 3D SonoAVC transvaginal ultrasound technology, particularly in infertile women. Therefore, this study aims to evaluate the usefulness of three-dimensional (3D) SonoAVC transvaginal ultrasound technology for antral follicle count and its correlation to conventional two-dimensional (2D) transvaginal ultrasound and serum levels of anti-Müllerian hormone in infertile women...
December 16, 2017: Reproductive Biology and Endocrinology: RB&E
https://www.readbyqxmd.com/read/29245952/the-humanized-anti-human-amhrii-mab-3c23k-exerts-an-anti-tumor-activity-against-human-ovarian-cancer-through-tumor-associated-macrophages
#6
Houcine Bougherara, Fariba Némati, André Nicolas, Gérald Massonnet, Martine Pugnière, Charlotte Ngô, Marie-Aude Le Frère-Belda, Alexandra Leary, Jérôme Alexandre, Didier Meseure, Jean-Marc Barret, Isabelle Navarro-Teulon, André Pèlegrin, Sergio Roman-Roman, Jean-François Prost, Emmanuel Donnadieu, Didier Decaudin
Müllerian inhibiting substance, also called anti-Müllerian hormone (AMH), inhibits proliferation and induces apoptosis of AMH type II receptor-positive tumor cells, such as human ovarian cancers (OCs). On this basis, a humanized glyco-engineered monoclonal antibody (3C23K) has been developed. The aim of this study was therefore to experimentally confirm the therapeutic potential of 3C23K in human OCs. We first determined by immunofluorescence, immunohistochemistry and cytofluorometry analyses the expression of AMHRII in patient's tumors and found that a majority (60 to 80% depending on the detection technique) of OCs were positive for this marker...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29234710/polypoid-endometriosis-mimicking-invasive-cancer-in-an-obese-postmenopausal-tamoxifen-user
#7
William T Jaegle, Jason C Barnett, Bridget R Stralka, Nicole P Chappell
Background: Tamoxifen is a medication often used for the treatment and prevention of breast cancer. It is classically associated with several gynecological side effects to include a thickened endometrial stripe, increased uterine polyp formation, and an increased risk of uterine cancer. Rarely tamoxifen use has been associated with proliferation of endometriosis often severe enough to mimic a late-stage gynecologic malignancy. Case: A 62-year-old Gravida 0 postmenopausal female with a medical history of severe obesity, infertility, and preventative tamoxifen use presented for evaluation of gross hematuria...
November 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29220296/carcinosarcomas-and-related-cancers-tumors-caught-in-the-act-of-epithelial-mesenchymal-transition
#8
Angela Pang, Mariana Carbini, Andre L Moreira, Robert G Maki
In this review, we outline the biology and management of patients with carcinosarcomas and related malignancies, which are often included under the broader concept of sarcomatoid carcinomas. Carcinosarcomas are unusual tumors that are commonly gynecologic in origin, where they are referred to as malignant mixed Müllerian tumors, but may appear in any anatomic site. Although a variety of hypotheses have been presented as to the biphasic nature of these tumors, carcinosarcomas seem to represent the best example in human cancers of the concept of epithelial-mesenchymal transition (EMT), in which the two parts of the tumor are genomically related to one another, as opposed to the mesenchymal component that represents a second neoplasm or (benign) reactive process...
December 8, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29194807/prevalence-of-the-amhr2-mutation-in-miniature-schnauzers-and-genetic-investigation-of-a-belgian-malinois-with-persistent-m%C3%A3-llerian-duct-syndrome
#9
M M Smit, K J Ekenstedt, K M Minor, C K Lim, Paj Leegwater, E Furrow
Persistent Müllerian duct syndrome (PMDS) is a sex-limited disorder in which males develop portions of the female reproductive tract. Important consequences of PMDS are cryptorchidism and its sequelae of infertility and increased risk of testicular cancer. Anti-Müllerian hormone (AMH) and its receptor (AMHR2) induce the regression of the Müllerian ducts in male embryos. In Miniature Schnauzer dogs, the genetic basis has been identified as an autosomal recessive nonsense mutation in AMHR2, but the allele frequency of the mutation is unknown...
December 1, 2017: Reproduction in Domestic Animals, Zuchthygiene
https://www.readbyqxmd.com/read/29151911/multiple-pulmonary-metastases-with-halo-sign-from-malignant-mixed-m%C3%A3-llerian-tumors
#10
Hong-Wei Tian, Wei-Bing Yang, Meng-Jie Yang, Jing-Yuan Liu, Jian-Chu Zhang, Xiao-Nan Tao, Qiong Zhou
The lungs are one of the most common organs to which cancer metastasizes, but are a location not common for uterine sarcoma. A malignant mixed Müllerian tumor (MMMT) of the uterus is an extremely rare and aggressive sarcoma, characterized by a mixture of epithelial and mesenchymal components. There are few reports regarding the pulmonary metastasis from MMMTs. The present study presents the case of a 58-year-old woman with hemoptysis and post-menopausal vaginal bleeding. The woman was initially diagnosed with invasive aspergillosis based on a chest computed tomography (CT) scan showing multiple pulmonary nodular opacities surrounded by a ground-glass attenuation halo (halo-sign)...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29137935/prostatic-adenocarcinoma-in-the-setting-of-persistent-m%C3%A3-llerian-duct-syndrome-a-case-report
#11
Zulfia McCroskey, Tracie M Koen, David J Lim, Mukul K Divatia, Steven S Shen, Alberto G Ayala, Jae Y Ro
Persistent Müllerian Duct Syndrome (PMDS) is a form of disordered sex development in which rudimentary Müllerian structures are identified in phenotypically and genotypically normal males. It is caused by defects in the anti-Müllerian hormone (AMH) system. Since patients with PMDS present with undescended testes, testosterone production by Leydig cells later in life is often decreased. The role of androgens in prostate cancerogenesis is well known. Cryptorchid testes and diminished testosterone levels in post pubertal life in patients with PMDS play a protective role against prostate cancer, and hence, prostate cancer is a rare event in patients with PMDS...
November 11, 2017: Human Pathology
https://www.readbyqxmd.com/read/29136604/extragenital-malignant-mixed-mesodermal-tumor-a-case-report
#12
Mauro Del Papa, Gabriele D'Amata, Fulvio Manzi, Luca Musmeci, Marco Crovaro, Carlo Buonocore, Gaetano Florio, Andrea Giannetti
INTRODUCTION: Primary malignant mixed mesodermal tumor (MMMt, also called malignant mixed Mullerian tumor and designated in the WHO classification of female genital tract neoplasms as carcinosarcoma) is an infrequent tumor that develops usually in the uterus and more rarely in the ovary. Extragenital tumor, including primary peritoneal MMMt, is an extremely rare and aggressive neoplasm with only few case reported in the literature. PRESENTATION OF CASE: We report a case of a 70-year's old female who presented with nausea and abdominal discomfort for 6 months...
November 9, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29117576/the-utility-of-anti-m%C3%A3-llerian-hormone-in-the-diagnosis-and-prediction-of-loss-of-ovarian-function-following-chemotherapy-for-early-breast-cancer
#13
RANDOMIZED CONTROLLED TRIAL
R A Anderson, J Mansi, R E Coleman, D J A Adamson, R C F Leonard
AIM: Chemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess whether analysis of anti-Müllerian hormone (AMH) using a sensitive automated assay could identify women who would not regain ovarian function after chemotherapy. METHODS: Data from women in the Ovarian Protection Trial in Premenopausal Breast Cancer Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue) for ovarian protection were analysed...
December 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29093011/primary-immunoprevention-of-epithelial-ovarian-carcinoma-by-vaccination-against-the-extracellular-domain-of-anti-m%C3%A3-llerian-hormone-receptor-ii
#14
Suparna Mazumder, Justin M Johnson, Valerie Swank, Nina Dvorina, Elizabeth Martelli, Jennifer Ko, Vincent K Tuohy
Epithelial ovarian carcinoma (EOC) is the most prevalent form of ovarian cancer in the United States, representing approximately 85% of all cases and causing more deaths than any other gynecologic malignancy. We propose that optimized control of EOC requires the incorporation of a vaccine capable of inducing safe and effective preemptive immunity in cancer-free women. In addition, we hypothesize that ovarian-specific self-proteins that are "retired" from autoimmune-inducing expression levels as ovaries age but are expressed at high levels in emerging EOC may serve as vaccine targets for mediating safe and effective primary immunoprevention...
November 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/29045555/reproductive-potential-and-performance-of-fertility-preservation-strategies-in-brca-mutated-breast-cancer-patients
#15
M Lambertini, O Goldrat, A R Ferreira, J Dechene, H A Azim, J Desir, A Delbaere, M-D t'Kint de Roodenbeke, E de Azambuja, M Ignatiadis, I Demeestere
BackgroundPreclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather conflicting clinical data are available. This study assessed the reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.Patients and MethodsThis was a retrospective analysis of two prospective studies investigating oocyte cryopreservation and ovarian tissue cryopreservation in newly diagnosed early breast cancer patients...
October 10, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29040187/palliative-radiation-therapy-for-recurrent-ovarian-cancer-efficacy-and-predictors-of-clinical-response
#16
Ginger Jiang, Tracy Balboni, Allison Taylor, Joyce Liu, Larissa J Lee
OBJECTIVE: This study aimed to report response rates and predictors of response to palliative radiotherapy (RT) for recurrent ovarian cancer. METHODS/MATERIALS: Database review identified 64 patients with symptomatic ovarian cancer recurrence who received a total of 76 courses of RT for 103 indications from March 2003 to August 2014. Radiotherapy indications were pain (44%), bleeding (32%), obstruction (15%), and other (9%). Responses were categorized as complete, partial, or none; all response (AR) was the sum of complete and partial responses...
October 17, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28984674/targeted-genomic-profiling-reveals-recurrent-kras-mutations-in-mesonephric-like-adenocarcinomas-of-the-female-genital-tract
#17
Jelena Mirkovic, Marie McFarland, Elizabeth Garcia, Lynette M Sholl, Neal Lindeman, Laura MacConaill, Fei Dong, Michelle Hirsch, Marisa R Nucci, Charles M Quick, Christopher P Crum, W Glenn McCluggage, Brooke E Howitt
Mesonephric adenocarcinoma most commonly arises in the cervix and is presumed to be derived from normal or hyperplastic mesonephric remnants. It is characterized by recurrent KRAS mutations and lack of PIK3CA/PTEN alterations. Adenocarcinomas of the uterine corpus and ovary characterized by morphologic and immunophenotypic similarities to mesonephric adenocarcinoma have been reported. The pathogenesis of these tumors, which have been designated "mesonephric-like adenocarcinomas" is unknown, and it has been debated whether these represent mesonephric adenocarcinomas that arise in the endometrium/ovary or endometrioid adenocarcinomas that closely mimic mesonephric adenocarcinoma...
February 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28921520/anti-m%C3%A3-llerian-hormone-and-risk-of-ovarian-cancer-in-nine-cohorts
#18
Seungyoun Jung, Naomi Allen, Alan A Arslan, Laura Baglietto, Aurelio Barricarte, Louise A Brinton, Brian L Egleston, Roni T Falk, Renée T Fortner, Kathy J Helzlsouer, Yutang Gao, Annika Idahl, Rudolph Kaaks, Vittorio Krogh, Melissa A Merritt, Eva Lundin, N Charlotte Onland-Moret, Sabina Rinaldi, Helena Schock, Xiao-Ou Shu, Patrick M Sluss, Paul N Staats, Carlotta Sacerdote, Ruth C Travis, Anne Tjønneland, Antonia Trichopoulou, Shelley S Tworoger, Kala Visvanathan, Elisabete Weiderpass, Anne Zeleniuch-Jacquotte, Joanne F Dorgan
Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression...
September 18, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28904505/embryo-cryopreservation-following-in-vitro-maturation-for-fertility-preservation-in-a-woman-with-mullerian-adenosarcoma-a-case-report
#19
Mehdi Mohsenzadeh, Mohammad A Khalili, Nasim Tabibnejad, Nahid Yari, Azam Agha-Rahimi, Mojgan Karimi-Zarchi
In-vitro maturation (IVM) of the immature oocytes recovered from the surgically removed ovarian tissue has been considered as a process for fertility preservation in patients with cancer. Fertility preservation for a woman with Mullerian adenocarcinoma. A 37-year-old woman with Mullerian adenocarcinoma was a candidate for ovarian resection. The immature oocytes were retrieved after ovarian resection from a 37-year-old woman with Mullerian adenocarcinoma. The oocytes underwent IVM and were fertilized using intracytoplasmic sperm injection (ICSI)...
April 2017: Journal of Human Reproductive Sciences
https://www.readbyqxmd.com/read/28878359/directed-differentiation-of-human-induced-pluripotent-stem-cells-into-fallopian-tube-epithelium
#20
Nur Yucer, Marie Holzapfel, Tilley Jenkins Vogel, Lindsay Lenaeus, Loren Ornelas, Anna Laury, Dhruv Sareen, Robert Barrett, Beth Y Karlan, Clive N Svendsen
The fallopian tube epithelium (FTE) has been recognized as a site of origin of high-grade serous ovarian cancer (HGSC). However, the absence of relevant in vitro human models that can recapitulate tissue-specific architecture has hindered our understanding of FTE transformation and initiation of HGSC. Here, induced pluripotent stem cells (iPSCs) were used to establish a novel 3-dimensional (3D) human FTE organoid in vitro model containing the relevant cell types of the human fallopian tube as well as a luminal architecture that closely reflects the organization of fallopian tissues in vivo...
September 6, 2017: Scientific Reports
keyword
keyword
87375
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"